论文部分内容阅读
IL-2是T 细胞分化中起关键作用的细胞激活物质。重组IL-2(rIL-2)在体外能激活淋巴细胞,现已用于癌症治疗。IL-2能提高一组NK 细胞的细胞毒活性,后者通过一种不受组织相容性抗原支配的机理杀伤肿瘤细胞。IL-2与细胞结合受体(IL-2R)有高度亲和力,并籍此发挥其功能。这些杂二聚体受体的轻链作为Tac、抗原可用单抗进行鉴定。可溶型IL-2受体(sIL-2R),由激活的淋巴样细胞所释放,仍保留与IL-2结合的能力,其血清水平可用ELISA 法测得。已知毛细胞白血病的瘤细胞表达IL-2R,sIL-2R 异常增高是该病的特征。据报道,在血细胞肿瘤、获得性免疫缺陷病、器官移植以及肉
IL-2 is a cell activating substance that plays a key role in the differentiation of T cells. Recombinant IL-2 (rIL-2) can activate lymphocytes in vitro and is now used for cancer therapy. IL-2 can increase the cytotoxic activity of a group of NK cells that kill tumor cells through a mechanism that is not dominated by histocompatibility antigens. IL-2 has a high affinity with the cell-binding receptor (IL-2R) and thus exerts its function. The light chain of these heterodimeric receptors is identified as Tac and the antigen can be identified as a monoclonal antibody. Soluble IL-2 receptor (sIL-2R), released by activated lymphoid cells, retains its ability to bind to IL-2, and its serum levels can be measured by ELISA. It is known that the tumor cells of hairy cell leukemia express IL-2R, and the abnormal increase of sIL-2R is characteristic of the disease. According to reports, in blood cell neoplasms, acquired immunodeficiency disease, organ transplantation and meat